Baxter International BAX Pharmaceuticals — Cost of Sales
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Baxter International in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The official record: Baxter International’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Baxter International's pharmaceuticals — cost of sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Baxter International's pharmaceuticals — cost of sales?
- Baxter International (BAX) reported pharmaceuticals — cost of sales of $458M in Q1 2026.
- How has Baxter International's pharmaceuticals — cost of sales changed year-over-year?
- Baxter International's pharmaceuticals — cost of sales increased by 15.7% year-over-year, from $396M to $458M.
- What is the long-term trend for Baxter International's pharmaceuticals — cost of sales?
- Over 3 years (2022 to 2025), Baxter International's pharmaceuticals — cost of sales has grown at a 11.2% compound annual growth rate (CAGR), from $1.29B to $1.78B.
- What does pharmaceuticals — cost of sales mean?
- The direct costs incurred to manufacture and distribute the products sold by the Pharmaceuticals segment.
- How do you interpret pharmaceuticals — cost of sales?
- Lower costs relative to sales indicate improved manufacturing efficiency and higher gross margins.
- How does pharmaceuticals — cost of sales compare across companies?
- Standard metric for manufacturing-heavy segments; peers typically aim to optimize this through supply chain management.